Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
Incannex secured a U.S. patent for IHL-42X covering compositions and methods for treating obstructive sleep apnea, with protection extending to at least July 2040. The company is advancing IHL-42X through the DReAMzz Phase 2 dose optimization study, having already received FDA Fast Track designation and central IRB approval.
Key figures
- Drug Name
- IHL-42X
- Phase Of Trial
- Phase 2
- Patent expiry date
- 9 July 2040
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.